The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-70
SponsorAnhui Provincial Hospital
About this trial
A multicenter, open-label, randomized, controlled study. It is proposed to evaluate the treatment plan of receiving 930mg polyene phosphatidylcholine injection one day before the operation, twice a day, and 930mg polyene phosphatidylcholine injection twice a day,combined with 100mg of magnesium isoglycyrrhizinate injection once a day,from the 1st to the 5th day after the operation. Compared with the monotherapy regimen of no liver protection treatment before the operation and receiving magnesium isoglycyrrhizinate injection 100mg once a day from the 1st to the 5th day after the operation.The efficacy and safety of treating postoperative liver function injury in patients undergoing laparoscopic hepatectomy for hepatocellular carcinoma were compared.
Eligibility criteria
Qualifiers
Diagnosed as HCC through imaging and laboratory tests, and capable of undergoing laparoscopic anatomical resection.
Surgical scope (defined by randomization stratification):Stratum 1: Major hepatectomy, involving the resection of at least 3 Couinaud liver segments, including right hemihepatectomy and extended right hemihepatectomy, etc.Stratum 2: Minor hepatectomy, involving the resection of no more than 2 Couinaud liver segments. This includes right posterior sectorectomy, right anterior sectorectomy, left lateral sectionectomy, single segmentectomy, etc.
During the operation, the Pringle method is used to block the first hepatic portal. Each block lasts ≤ 15 minutes, and the blocking procedure is performed 2 to 4 times.
Age: 18 - 80 years old. Gender: Open to both male and female. Body Mass Index (BMI): 18.5 - 28 kg/m².
Disqualifiers
Reserve liver vascular damage, including: reconstruction after severance, ligation, embolization, thrombosis, etc
Combined with abnormal coagulation function (prothrombin time prolonged by more than 3 seconds)
Combining obstructive jaundice, severe heart disease, severe kidney disease and other serious illnesses
During the operation, microwave treatment or a combination of microwave treatment was adopted
Trial design
Treatments tested in this trial
- Experimental Group
- control group
Treatment groups
96 Participants
are divided into 2 treatment groupsLocations
1Anhui Provincial Hospital230000, HefeiAnhui, China
Sponsors and collaborators
Anhui Provincial Hospital
Lead sponsor
The First Affiliated Hospital of Anhui Medical University
Collaborator
The Second Hospital of Anhui Medical University
Collaborator
The First Affiliated Hospital of Bengbu Medical University
Collaborator
First Affiliated Hospital of Wannan Medical College
Collaborator
Source ClinicalTrials.gov